Eli Lilly and Company, Johnson & Johnson, Pfizer, AbbVie, and Merck & Co., Inc. are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of companies that research, develop, manufacture, or sell medicines and related treatments. For investors, their performance can depend on factors such as drug-trial results, regulatory approvals, patents, sales, and competition. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
NYSE LLY traded up $11.39 during trading hours on Tuesday, reaching $1,423.34. 964,454 shares of the company's stock were exchanged, compared to its average volume of 2,959,456. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00. The stock has a market cap of $1.34 trillion, a PE ratio of 46.21, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40. The company has a current ratio of 1.39, a quick ratio of 1.00 and a debt-to-equity ratio of 1.17. The firm has a fifty day moving average of $1,220.13 and a 200-day moving average of $1,102.83.
Read Our Latest Research Report on LLY
Johnson & Johnson (JNJ)
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.
Shares of NYSE JNJ traded down $0.72 during trading on Tuesday, reaching $281.39. The company had a trading volume of 2,280,787 shares, compared to its average volume of 7,944,055. The stock has a market cap of $677.40 billion, a PE ratio of 42.65, a PEG ratio of 2.73 and a beta of 0.22. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The business's 50 day moving average price is $266.18 and its 200-day moving average price is $248.62. Johnson & Johnson has a 52 week low of $189.05 and a 52 week high of $283.25.
Read Our Latest Research Report on JNJ
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Pfizer stock traded down $0.06 during midday trading on Tuesday, hitting $29.18. 12,170,075 shares of the stock were exchanged, compared to its average volume of 39,831,906. The company has a fifty day simple moving average of $28.77 and a two-hundred day simple moving average of $26.92. The stock has a market capitalization of $166.29 billion, a PE ratio of 41.73, a P/E/G ratio of 2.04 and a beta of 0.31. Pfizer has a 52 week low of $23.62 and a 52 week high of $31.44. The company has a quick ratio of 0.96, a current ratio of 1.42 and a debt-to-equity ratio of 0.67.
Read Our Latest Research Report on PFE
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Shares of ABBV stock traded up $0.28 during trading hours on Tuesday, hitting $293.58. 1,192,460 shares of the company were exchanged, compared to its average volume of 6,322,229. The business has a 50 day moving average of $272.71 and a two-hundred day moving average of $239.42. AbbVie has a 52 week low of $190.75 and a 52 week high of $302.93. The company has a market capitalization of $518.93 billion, a PE ratio of 50.57, a PEG ratio of 1.34 and a beta of 0.20.
Read Our Latest Research Report on ABBV
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Shares of NYSE:MRK traded down $2.22 during midday trading on Tuesday, reaching $146.54. The company had a trading volume of 1,857,492 shares, compared to its average volume of 10,595,797. The stock has a market cap of $361.53 billion, a PE ratio of 151.15, a P/E/G ratio of 6.83 and a beta of 0.13. Merck & Co., Inc. has a 1-year low of $87.26 and a 1-year high of $156.92. The business's 50 day moving average price is $146.39 and its 200 day moving average price is $127.82. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.
Read Our Latest Research Report on MRK
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
